Decision: Favourable
Study Title:
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents
NREC Code:
21-NREC-CT-126
Decision:
Favourable
Meeting Date:
03/11/2021
Study Type:
CT application
Principal Investigator:
Professor Ray McDermott
PI Institution:
Tallaght University Hospital
Sponsor:
Unicancer, Bayer